toid arthritis[J]. Arthritis Rheum, 1988, 31(3): 315-324.
[5] Fransen J, van-Riel P L. The Disease Activity Score and the EULAR response criteria[J]. Rheum Dis Clin North Am, 2009, 35(4): 745-757.
[6] Li H, Luo W, Zeng Q, *et al*. Method for the determination of blood methotrexate by high performance liquid chromatography with online post-column electrochemical oxidation and fluorescence detection[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 845(1): 164-168.
[7] Inoue S, Hashiguchi M, Kawai S, *et al*. Erythrocyte methotrexate-polyglutamate assay using fluorescence polarization immunoassay technique: application to the monitoring of patients with rheumatoid arthritis[J]. Yakugaku Zasshi, 2009, 129(8): 1001-1005.
[8] Mor A, Abramson S B, Pillinger M H. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction[J]. Clin Immun, 2005, 115(2): 118-128.
[9] Cutolo M, Sulli A, Pizzorni C, *et al*. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis[J]. Ann Rheum Dis, 2001, 60(8): 729-735.
[10] Schalhorn A, Sauer H, Wilmanns W, *et al*. Pharmacokinetics of erythrocyte methotrexate after high-dose methotrexate[J]. Cancer Chemother Pharmacol, 1982, 9(1): 65-69.
[11] Schroder H, Clausen N, Ostergaard E, *et al*. Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment[J]. Cancer Chemother Pharmacol, 1986, 16(2): 190-193.
[12] 中华医学会风湿病学分会. 类风湿关节炎诊治指南(草案)[J]. 中华风湿病学杂志, 2003, 7(4): 250-254.
[13] 尉世同, 孙永华, 邹巧菲, 等. 双醋瑞因联合甲氨喋呤治疗类风湿关节炎的临床研究[J]. 第三军医大学学报, 2010, 32(19): 2112-2114.
[14] Visser K, van-der-Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature[J]. Ann Rheum Dis, 2009, 68(7): 1094-1099.
[15] Stamp L K, O'Donnell J L, Chapman P T, *et al*. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy[J]. Arthritis Rheum, 2010, 62(2): 359-368.
[16] Seideman P. Methotrexate--the relationship between dose and clinical effect[J]. Br J Rheumatol, 1993, 32(8): 751-753.
[17] Dervieux T, Furst D, Lein D O, *et al*. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis[J]. Arthritis Rheum, 2004, 50(9): 2766-2774.
[18] Lafforgue P, Monjanel-Mouterde S, Durand A, *et al*. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis[J]. J Rheumatol, 1995, 22(5): 844-849.
[19] Angelis-Stoforidis P, Vajda F J, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis[J]. Clin Exp Rheumatol, 1999, 17(3): 313-320.
[20] Tishler M, Caspi D, Graff E, *et al*. Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis[J]. Br J Rheumatol, 1989, 28(5): 422-423.
[21] Dervieux T, Furst D, Lein D O, *et al*. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study[J]. Ann Rheum Dis, 2005, 64(8): 1180-1185.
[22] Katchamart W, Trudeau J, Phumethum V, *et al*. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis[J] Ann Rheum Dis, 2009, 68(7): 1105-1112.

(收稿:2010-10-27 修回:2010-11-23)
(编辑 龙 亮)

欢迎订购《疑难先天性心脏病介入治疗与图解》



由宋治远、朱鲜阳、秦永文、张玉顺等教授主编的《疑难先天性心脏病介入治疗与图解》将于2011年1月由军事医学科学出版社正式出版。该书编者均为国内一流先天性心脏病介入治疗专家,具有丰富的临床经验,总结了临床常见及少见的疑难先天性心脏病介入治疗方法。全书共10章,收集了各种疑难先天性心脏病180例患者的800余幅影像资料,系统介绍了室间隔缺损、房间隔缺损、动脉导管未闭、主动脉缩窄以及复合畸形等复杂先天性心脏病介入治疗操作技巧与经验教训。本书贴近临床、图文并茂、形象具体、通俗易懂,既有临床操作技巧,又有经验教训分享,是一本难得的具有先进水平的临床参考书,相信会成为广大先天性心脏病介入治疗医师的良师益友。

本书定价198.00元,如需购买请与本刊编辑部联系。

联系人:王 红 **电话**:(023)68752782,68752187

E-mail:whong@mail.tmmu.com.cn